ANRO

Alto Neuroscience, Inc.

Fundamental data last updated:June 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/12/2026

Business Summary

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

 


Analyze ANRO on TradingView

VALUATION

P/E

-8.95

Market Cap ($M USD)

$709.60M

Forward P/E

-19.86

PEG

-0.36

PRICE TO SALES

0.00

PRICE TO BOOK

2.73

EV / EBITDA

-6.21

5-Year Average P/E

Free Cash Flow Yield

-8.86%

DCF Value

$5.91

Graham Number

N/A

Price to FCF

-11.29

EV to FCF

-7.18

Earnings Yield

-11.17%

FCF Yield

-8.86%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.26

Next Year EPS Growth Estimate

-$1.02

Next Year Revenue Growth Estimate

$21.15B

Return on Equity (ROE)

-47.22%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.03

Piotroski F-Score

2

Altman Z-Score

12.17

Return on Invested Capital (ROIC)

20.86%

Current Ratio

20.52

Quick Ratio

20.52

Net Debt to EBITDA

3.55

Interest Coverage

22.72

Gross Profit margin

0.00%

FCF PER SHARE

$-1.91

REVENUE PER SHARE

$0.00

Analyze ANRO on TradingView

Gainseekers Quantitative Analysis

Summary

ANRO Alto Neuroscience, Inc. presents a perplexing valuation scenario. The stock has traded significantly above its DCF value, suggesting a market mispricing. Despite a daunting negative earnings yield, the forward P/E indicates optimism for future profitability. The Altman Z-score of 12.30 signals robust financial health, yet the negative ROIC and earnings yield raise red flags about current operational efficiency. Investors must weigh these contradictions carefully.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, ANRO is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, potentially enhancing R&D efficiency. This adaptability could offer a competitive edge in a rapidly evolving landscape.

The Bull Case

For the bullish investor, ANRO's low debt-to-equity ratio and impressive Altman Z-score highlight financial resilience. The forward PEG ratio below 1.0 suggests undervaluation relative to growth expectations. Despite a low Piotroski F-Score, the company's high current ratio indicates strong liquidity, providing a buffer for strategic investments. These factors could appeal to those seeking growth at a reasonable price.

The Bear Case

However, ANRO faces significant structural challenges. The negative price to FCF and earnings yield underscore a troubling cash flow situation. With a price/book ratio over 5, the stock appears overvalued relative to its assets. Additionally, trading close to its 52-week high suggests technical overextension, raising caution for potential investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$34.60

Institutional Ownership %

1-Year Beta

1.65

Insider Buying % (6 Mo)

Distance to 52-Week High

40.66%

Distance to 52-Week Low

89.37%

EARNINGS SURPRISE %

-42.86%

50-DAY SMA

$23.22

200-DAY SMA

$15.09

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.